X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3749) 3749
Publication (412) 412
Book Review (86) 86
Book Chapter (27) 27
Conference Proceeding (7) 7
Dissertation (4) 4
Government Document (4) 4
Data Set (2) 2
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2410) 2410
index medicus (2056) 2056
pegylated liposomal doxorubicin (1784) 1784
oncology (1635) 1635
female (1403) 1403
chemotherapy (1145) 1145
cancer (1038) 1038
liposomal doxorubicin (1011) 1011
pharmacology & pharmacy (865) 865
animals (784) 784
middle aged (763) 763
aged (701) 701
doxorubicin - administration & dosage (641) 641
adult (583) 583
antineoplastic combined chemotherapy protocols - therapeutic use (567) 567
doxorubicin (561) 561
ovarian cancer (559) 559
male (525) 525
treatment outcome (510) 510
ovarian neoplasms - drug therapy (505) 505
nanoparticles (494) 494
drug delivery systems (492) 492
liposomes (492) 492
antineoplastic agents - therapeutic use (486) 486
anthracyclines (474) 474
paclitaxel (419) 419
care and treatment (408) 408
doxorubicin - analogs & derivatives (379) 379
therapy (377) 377
mice (354) 354
drugs (344) 344
drug-delivery (343) 343
antineoplastic agents - administration & dosage (334) 334
doxorubicin - adverse effects (324) 324
doxorubicin - therapeutic use (323) 323
neoplasms - drug therapy (318) 318
trial (313) 313
carcinoma (311) 311
cell line, tumor (307) 307
tumors (305) 305
phase-ii trial (302) 302
phase-ii (299) 299
research (294) 294
breast cancer (291) 291
pharmacokinetics (291) 291
chemistry, multidisciplinary (273) 273
toxicity (271) 271
drug therapy (269) 269
drug delivery (267) 267
hematology (267) 267
article (264) 264
antineoplastic combined chemotherapy protocols - adverse effects (263) 263
obstetrics & gynecology (262) 262
analysis (261) 261
polyethylene glycols - administration & dosage (258) 258
medicine & public health (253) 253
aged, 80 and over (252) 252
health aspects (251) 251
in-vivo (251) 251
breast-cancer (249) 249
solid tumors (246) 246
breast neoplasms - drug therapy (244) 244
disease-free survival (242) 242
pegylated-liposomal doxorubicin (234) 234
vehicles (232) 232
nanoscience & nanotechnology (230) 230
hematology, oncology and palliative medicine (228) 228
antibiotics, antineoplastic - administration & dosage (221) 221
neoplasm recurrence, local - drug therapy (220) 220
antitumor-activity (217) 217
drug resistance, neoplasm (214) 214
in-vitro (214) 214
ovarian neoplasms - pathology (212) 212
antineoplastic agents - adverse effects (210) 210
cisplatin (210) 210
phase-iii trial (210) 210
nanotechnology (192) 192
antineoplastic agents - pharmacology (189) 189
cardiotoxicity (189) 189
drug administration schedule (187) 187
nanomedicine (186) 186
carboplatin (185) 185
combination (185) 185
clinical trials (179) 179
gemcitabine (176) 176
medicine, research & experimental (176) 176
gynecologic-oncology-group (174) 174
metastatic breast-cancer (172) 172
polyethylene glycols - adverse effects (170) 170
antineoplastic combined chemotherapy protocols - administration & dosage (168) 168
efficacy (167) 167
multiple myeloma (165) 165
randomized phase-iii (165) 165
doxorubicin - pharmacology (164) 164
neoplasm staging (164) 164
metastasis (162) 162
cyclophosphamide (161) 161
biochemistry & molecular biology (159) 159
dose-response relationship, drug (156) 156
prognosis (155) 155
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3698) 3698
German (28) 28
French (16) 16
Polish (14) 14
Spanish (10) 10
Japanese (9) 9
Russian (6) 6
Korean (2) 2
Turkish (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2006, Volume 106, Issue 4, pp. 848 - 858
BACKGROUND. Pegylated liposomal doxorubicin has pharmacologic and safety advantages over conventional doxorubicin. METHODS. For this noninteriority trial, 192... 
Dexamethasone | Neutropenic fever | Drug toxicity | Multiple myeloma | Liposomes | Drug resistance | Doxorubicin | Pegylated liposomal doxorubicin | Vincristine | Neoplasms | dexamethasone | 1ST-LINE TREATMENT | multiple myeloma | vincristine | ONCOLOGY-GROUP | liposomes | COMBINATION THERAPY | neutropenic fever | CONVENTIONAL DOXORUBICIN | TRANSPLANTATION | pegylated liposomal doxorubicin | THALIDOMIDE PLUS DEXAMETHASONE | KAPOSIS-SARCOMA | ONCOLOGY | drug toxicity | REDUCED-DOSE DEXAMETHASONE | VAD | doxorubicin | drug resistance | neoplasms | DVD-T | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Fever - chemically induced | Multiple Myeloma - drug therapy | Doxorubicin - analogs & derivatives | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Administration, Oral | Catheterization, Central Venous | Treatment Outcome | Polyethylene Glycols - administration & dosage | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Infusions, Intravenous | Doxorubicin - adverse effects | Pharmaceutical research | Drugs | Myelocytic leukemia | Reports | Nonlymphoid leukemia | Research | Drug therapy, Combination | Drug therapy | Health aspects
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 04/2017, Volume 31, Issue 4, pp. np - n/a
Journal Article
Drugs, ISSN 0012-6667, 2011, Volume 71, Issue 18, pp. 2531 - 2558
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2012, Volume 8, Issue 1, pp. 71 - 80
Abstract The in vivo efficacy of doxorubicin (DOX)-loaded poly(γ-benzyl l -glutamate)- block -hyaluronan (PBLG23 - b -HYA10 )-based polymersomes (PolyDOX) was... 
Internal Medicine | Hyaluronan | Ehrlich ascites tumor (EAT) | Antitumor activity | Doxorubicin | Polymersomes | MEDICINE, RESEARCH & EXPERIMENTAL | BLOCK-COPOLYMERS | SOLID TUMORS | DRUG-DELIVERY | RECEPTOR | NANOSCIENCE & NANOTECHNOLOGY | VASCULAR-PERMEABILITY | CANCER | CARRIERS | PACLITAXEL | LIPOSOMAL DOXORUBICIN | ENDOCYTOSIS HARE | Doxorubicin - blood | Doxorubicin - therapeutic use | Drug Carriers - adverse effects | Hyaluronic Acid - therapeutic use | Nanoparticles - chemistry | Antineoplastic Agents - chemical synthesis | Humans | Drug Carriers - administration & dosage | Polyglutamic Acid - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Nanoparticles - adverse effects | Drug Carriers - chemistry | Polyglutamic Acid - analogs & derivatives | Antineoplastic Agents - adverse effects | Female | Hyaluronic Acid - blood | Hyaluronic Acid - adverse effects | Doxorubicin - administration & dosage | Endocytosis - immunology | Technetium - chemistry | Rabbits | Hyaluronic Acid - administration & dosage | Hyaluronic Acid - chemistry | Carcinoma, Ehrlich Tumor - drug therapy | Doxorubicin - chemical synthesis | Polyglutamic Acid - blood | Polyglutamic Acid - chemistry | Animals | Hyaluronic Acid - analogs & derivatives | Antineoplastic Agents - blood | Hyaluronan Receptors - immunology | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Polyglutamic Acid - therapeutic use | Neoplasms, Experimental - drug therapy | Doxorubicin - adverse effects | Polyglutamic Acid - adverse effects | Anthracyclines | Ascites | Hyaluronic acid | Tumors | Polymers | Chemical Sciences
Journal Article
Nuclear Medicine and Biology, ISSN 0969-8051, 2009, Volume 36, Issue 5, pp. 515 - 524
Journal Article
Nanomedicine, ISSN 1743-5889, 10/2015, Volume 10, Issue 19, pp. 2963 - 2971
Aim: To test the efficacy and toxicity of exosomal doxorubicin (exoDOX) compared with free doxorubicin. Materials & methods: The cytotoxic effects of exoDOX... 
toxicity | breast cancer | nanomedicine | exosomal doxorubicin | drug delivery | exosome | NANOPARTICLE TRACKING ANALYSIS | PEGYLATED LIPOSOMAL DOXORUBICIN | DENDRITIC CELLS | CANCER CELLS | VESICLES | CARDIOTOXICITY | NANOSCIENCE & NANOTECHNOLOGY | MICRORNAS | MEDIATED TRANSFER | DELIVERY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | MICE
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2015, Volume 210, pp. 198 - 207
Combinations of topoisomerase inhibitors I and II have been found to synergistically inhibit cancer cell growth in vitro, yet clinical studies of these types... 
Synergistic | Chemotherapy | Drug combinations | Polymer drug conjugate | SINGLE-AGENT CHEMOTHERAPY | CHEMISTRY, MULTIDISCIPLINARY | OVARIAN-CARCINOMA | CELL LUNG-CANCER | HUMAN BREAST-CARCINOMA | ZOLEDRONIC ACID | PHASE-I TRIAL | ENDOTHELIAL-CELLS | IRINOTECAN | PHARMACOLOGY & PHARMACY | PEGYLATED-LIPOSOMAL DOXORUBICIN | CYTOTOXIC AGENTS | Hyaluronic Acid - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Camptothecin - chemistry | Apoptosis - drug effects | Humans | Hyaluronic Acid - chemistry | Topoisomerase I Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - chemistry | Topoisomerase II Inhibitors - administration & dosage | Doxorubicin - chemistry | Neoplasms - drug therapy | Drug Synergism | Antineoplastic Agents, Phytogenic - administration & dosage | Animals | Topoisomerase II Inhibitors - chemistry | Tumor Burden - drug effects | Cell Line, Tumor | Camptothecin - administration & dosage | Female | Mice, Inbred BALB C | Neoplasms - pathology | Topoisomerase I Inhibitors - chemistry | Doxorubicin - administration & dosage | Hyaluronic acid | Anthracyclines | Analysis | Medical research | Medicine, Experimental | Drug therapy, Combination | Polymers | Index Medicus | synergistic | polymer drug conjugate | chemotherapy | drug combinations
Journal Article
Life Sciences, ISSN 0024-3205, 05/2018, Volume 200, pp. 26 - 30
Doxorubicin (Dox) is a valuable anticancer drug for hematologic and solid tumors. Yet, it can cause multi-organ toxicities in various patients. Since toxicity... 
Oxidative stress | Toxicity | Doxorubicin | Multi-organ | Mechanism | MEDICINE, RESEARCH & EXPERIMENTAL | PEGYLATED LIPOSOMAL DOXORUBICIN | CELLS | RATS | MEDIATED APOPTOSIS | OVARIAN-CANCER | NANOPARTICLES | INDUCED CARDIOTOXICITY | IN-VITRO | RADIATION RECALL | PHARMACOLOGY & PHARMACY | Medicine, Experimental | Medical colleges | Medical research | Anthracyclines | Green products | Index Medicus
Journal Article
Journal Article